Antigen binding molecules targeting SARS-CoV-2
US11987616B2 · kind B2 · utility
0Cited by
9References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 15, 2023 |
| Grant date | May 21, 2024 |
| Priority date | — |
| Expiry date | Feb 15, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides, in various embodiments, polypeptides (e.g., camelid antibodies and antigen binding fragments thereof) that specifically bind to Spike glycoprotein of severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2-Spike). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating viral infections (e.g., COVID-19).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.